PURPOSE: The aim of this study was to evaluate the efficacy and toxicity of concurrent chemoradiotherapy (CRT) with gemcitabine plus regional hyperthermia (HT) for locally advanced pancreatic carcinoma (LAPC). MATERIALS AND METHODS: A total of 29 patients with LAPC treated with concurrent CRT using gemcitabine were retrospectively analyzed. Radiotherapy was administered with a median total dose of 61.2 Gy. Of the 29 patients, 20 (69%) also underwent regional HT during CRT (CRHT group). The remaining 9 patients did not receive regional HT (CRT group) because of a common bile duct stent placement, patient refusal, older age, or obesity. The efficacy and toxicity of the treatments and the predictors of good outcome were evaluated. RESULTS: The median disease progression-free and overall survival times were significantly better for the CRHT group than for the CRT group (8.8 vs. 4.9 months, P = 0.02, and 18.6 vs. 9.6 months, P = 0.01), respectively. Grade 3-4 hematological toxicities for the CRHT group were detected in eight patients (40%) and grade 3 nonhematologic toxicity in one (diarrhea). CONCLUSION: Concurrent CRT using gemcitabine with regional HT may be a feasible and promising regimen for LAPC, and the results justified further evaluation in a large number of patients to confirm its definite benefit.
PURPOSE: The aim of this study was to evaluate the efficacy and toxicity of concurrent chemoradiotherapy (CRT) with gemcitabine plus regional hyperthermia (HT) for locally advanced pancreatic carcinoma (LAPC). MATERIALS AND METHODS: A total of 29 patients with LAPC treated with concurrent CRT using gemcitabine were retrospectively analyzed. Radiotherapy was administered with a median total dose of 61.2 Gy. Of the 29 patients, 20 (69%) also underwent regional HT during CRT (CRHT group). The remaining 9 patients did not receive regional HT (CRT group) because of a common bile duct stent placement, patient refusal, older age, or obesity. The efficacy and toxicity of the treatments and the predictors of good outcome were evaluated. RESULTS: The median disease progression-free and overall survival times were significantly better for the CRHT group than for the CRT group (8.8 vs. 4.9 months, P = 0.02, and 18.6 vs. 9.6 months, P = 0.01), respectively. Grade 3-4 hematological toxicities for the CRHT group were detected in eight patients (40%) and grade 3 nonhematologic toxicity in one (diarrhea). CONCLUSION: Concurrent CRT using gemcitabine with regional HT may be a feasible and promising regimen for LAPC, and the results justified further evaluation in a large number of patients to confirm its definite benefit.
Authors: J van der Zee; D González González; G C van Rhoon; J D van Dijk; W L van Putten; A A Hart Journal: Lancet Date: 2000-04-01 Impact factor: 79.321
Authors: R D Issels; S Abdel-Rahman; C Wendtner; M H Falk; V Kurze; H Sauer; U Aydemir; W Hiddemann Journal: Eur J Cancer Date: 2001-09 Impact factor: 9.162
Authors: S M de Lange; C J van Groeningen; O W M Meijer; M A Cuesta; J A Langendijk; J M G H van Riel; H M Pinedo; G J Peters; S Meijer; B J Slotman; G Giaccone Journal: Eur J Cancer Date: 2002-06 Impact factor: 9.162
Authors: V E Kouloulias; J R Kouvaris; K S Nikita; B C Golematis; N K Uzunoglu; K Mystakidou; C Papavasiliou; L Vlahos Journal: Int J Hyperthermia Date: 2002 May-Jun Impact factor: 3.914
Authors: C J McGinn; M M Zalupski; I Shureiqi; J M Robertson; F E Eckhauser; D C Smith; D Brown; G Hejna; M Strawderman; D Normolle; T S Lawrence Journal: J Clin Oncol Date: 2001-11-15 Impact factor: 44.544
Authors: Ellen L Jones; Leonard R Prosnitz; Mark W Dewhirst; P Kelly Marcom; Patricia H Hardenbergh; Lawrence B Marks; David M Brizel; Zeljko Vujaskovic Journal: Clin Cancer Res Date: 2004-07-01 Impact factor: 12.531
Authors: R de Wit; J van der Zee; M E van der Burg; W H Kruit; A Logmans; G C van Rhoon; J Verweij Journal: Br J Cancer Date: 1999-07 Impact factor: 7.640
Authors: H Petra Kok; Erik N K Cressman; Wim Ceelen; Christopher L Brace; Robert Ivkov; Holger Grüll; Gail Ter Haar; Peter Wust; Johannes Crezee Journal: Int J Hyperthermia Date: 2020 Impact factor: 3.914
Authors: Yang Guo; Andreas Ziesch; Sandra Hocke; Eric Kampmann; Stephanie Ochs; Enrico N De Toni; Burkhard Göke; Eike Gallmeier Journal: J Cell Mol Med Date: 2014-10-21 Impact factor: 5.310
Authors: Claus Schäfer; Hendrik Seeliger; Dominik C Bader; Gerald Assmann; Denise Buchner; Yang Guo; Andreas Ziesch; Andreas Palagyi; Stephanie Ochs; Rüdiger P Laubender; Andreas Jung; Enrico N De Toni; Thomas Kirchner; Burkhard Göke; Christiane Bruns; Eike Gallmeier Journal: J Cell Mol Med Date: 2012-08 Impact factor: 5.310
Authors: Adela Ademaj; Danai P Veltsista; Pirus Ghadjar; Dietmar Marder; Eva Oberacker; Oliver J Ott; Peter Wust; Emsad Puric; Roger A Hälg; Susanne Rogers; Stephan Bodis; Rainer Fietkau; Hans Crezee; Oliver Riesterer Journal: Cancers (Basel) Date: 2022-01-26 Impact factor: 6.639